Association of the CYP19A1 rs700518 Polymorphism with Selected Markers of Bone Metabolism in Women with Hyperandrogenism

Izabela Uzar 1, Anna Bogacz 2,*, Elżbieta Sowińska-Przepieria 3, Krzysztof Piątek 4, Filip Przerwa 1, Marlena Wolek 2 and Boguslaw Czerny 1,2

1 Department of Pharmacology and Pharmacoeconomics, Pomeranian Medical University, 71-230 Szczecin, Poland; uzar@wp.pl (I.U.); fmprzerwa@gmail.com (F.P.); boguslaw.czerny@iwnirz.pl (B.C.)
2 Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibers and Medicinal Plants, 62-064 Plewiska, Poland; marlena.wolek@iwnirz.pl
3 Department of Endocrinology, Metabolic Diseases and Internal Diseases, Pomeranian Medical University, 71-252 Szczecin, Poland; elzbieta.sowinska@pum.edu.pl
4 Department of Gynecology and Obstetrics, Collegium Medicum, University of Zielona Góra, 65-001 Zielona Góra, Poland; krzysztofpiatek.jr@gmail.com
* Correspondence: aniabogacz23@o2.pl

Abstract: Hyperandrogenism is the most common endocrine disorder in women, characterized by an imbalance of normal estrogen and androgen levels in the blood. Androgens play an important role in the female body because they influence bone mineral density (BMD), body mass composition, muscle mass, mental state, and the regulation of sexual function. The reduced activity of aromatase, due to mutations in the CYP19A1 gene, reduces the estrogen pool in favor of androgens. Clinically, aromatase deficiency causes hyperandrogenism in women. Therefore, the aim of the study was to assess the effect of the CYP19A1 gene polymorphism on selected markers of bone metabolism and hormonal parameters in women with hyperandrogenism. The study group was comprised of 80 young women with hyperandrogenism who underwent measurements of bone mineral density (BMD), and determination of hormonal and metabolic parameters. Enzyme immunoassays were used to measure leptin, total sRANKL (free and bound RANKL), osteoprotegerin, and total 25-OH Vitamin D. An analysis of the CYP19A1 gene polymorphisms was performed using the real-time PCR method. The GG genotype of the CYP19A1 rs700518 polymorphism turned out to be associated with: FEI (Free Estradiol Index), SHGB concentration, estradiol concentration, and insulin concentration determined in the glucose tolerance test 60’ compared to AG and AA genotypes. Patients with the AG genotype had a higher ratio of android to gynoid fat and a greater content of visceral adipose tissue. Higher visceral tissue content may reduce BMD. In conclusion, the study showed that the CYP19A1 rs700518 polymorphism may be associated with the distribution of adipose tissue in young women with hyperandrogenism. These results suggest that patients with the AG genotype may develop osteoporosis.

Keywords: hyperandrogenism; gene polymorphism; CYP19A1; bone metabolism

1. Introduction

Hyperandrogenism (an excessive level of androgens in the female body) is a serious health problem affecting 5–10% of women of reproductive age. In total, 80% of hyperandrogenism is associated with PCOS (polycystic ovary syndrome), whereas in about 15%, it is impossible to associate hyperandrogenism with any disease entity (idiopathic hyperandrogenism). In adolescence, especially in the first years after the menarche, dysfunction of the hypothalamus may occur due to excessive psycho-emotional stress and physical exertion or due to the increasing scope of responsibilities (e.g., schoolwork). Behavioral disorders, eating disorders, or adolescent depression that occur at this time affect the neurosecretion of the hypothalamus to such an extent that they can lead to secondary amenorrhea [1].
The long-term effect of the psychogenic factor is one of the causes of functional hypothalamic amenorrhea (FHA). The frequency of this disorder is estimated at 2.6–8.5%; however, in the case of girls exposed to chronic stress, e.g., due to competitive training in certain sports, the incidence of FHA may be as high as 100% [2,3]. Other causes of excessive androgenization in women of reproductive age are ovarian tumors, adrenal tumors, and non-classical congenital adrenal hyperplasia (NCAH) [4]. The most common direct cause of hyperandrogenism is the excessive production of androgens in the ovaries or adrenal glands. Sometimes clinical signs of hyperandrogenism are observed with normal serum androgen concentrations [5]. In the female body, testosterone and androstenedione are converted into estrogens, estradiol, and estrone [6].

The enzyme responsible for converting androgens to estrogens is aromatase. This enzyme belongs to the cytochrome P450 family and is encoded by the **CYP19A1** gene located on chromosome 15q21.2 [7,8]. Reduced activity of this enzyme, due to mutations in the **CYP19A1** gene, reduces the estrogen pool in favor of androgens. Clinically, aromatase deficiency causes hyperandrogenism in women. Symptoms of aromatase deficiency are progressive virilization (change in body structure, hirsutism, alopecia). Girls do not develop secondary sexual characteristics properly during puberty [9]. The **CYP19A1** polymorphism is related to bone mineral density (BMD), and rs700518 is one of the most studied polymorphisms in association with BMD and osteoporosis [10,11].

It is now known that hyperandrogenism is a multi-gene disorder influenced by epigenetic and environmental factors. The search for genetic determinants aims to improve diagnostics and therapeutic possibilities. The aim of the study was to assess the effect of the **CYP19A1** gene polymorphism on selected markers of bone metabolism and hormonal parameters in women with hyperandrogenism, and whether the presence of polymorphisms of this gene may be a clinically useful marker in the prevention and treatment of disorders resulting from the hormonal disorders associated with hyperandrogenism. A further aim was to examine what role aromatase gene polymorphisms may have in the pathogenesis of hyperandrogenism in young women. Explaining the genetic determinants of this type of disorder may be important for devising methods of treating hormonal disorders to prevent subsequent menstrual, metabolic, and bone metabolism disorders.

2. Materials and Methods

2.1. Patients

The study group consisted of 80 young women aged 18 to 35 with hyperandrogenism with secondary functional amenorrhea (FHA) attending the Department of Endocrinology, Metabolic Diseases, and Internal Diseases at the Pomeranian Medical University in Szczecin (Poland). The inclusion criteria for the genetic research were as follows: (1) Caucasian race, (2) at least six months of amenorrhea preceded by at least three years of oligomenorrhea, (3) no current history of chronic pharmacotherapy, and (4) a lack of major abnormalities upon physical examination. The exclusion criteria were: (1) polycystic ovary syndrome, congenital adrenal hyperplasia, or premature ovarian failure diagnosed on the basis of medical history, gynecological exam, and laboratory tests, (2) low birth weight or preterm birth, (3) at least one confirmed episode of an eating disorder, (4) poor diet during childhood or puberty, (5) episodes of impaired growth and body mass gain, (6) extensive participation in sports that may have influenced bone mineralization, (7) metabolic disorders that may be associated with decreased bone mineralization, (8) prolonged use of stimulants or drugs that may affect bone metabolism, and (9) a family history of osteoporosis.

The study was approved by the Ethical Committee of the Pomeranian Medical University (No. KB-0012/115/15). It was conducted in accordance with the Helsinki Declaration (1975, revised 2000). Written informed consent was obtained from all the participants.
2.2. Determination of Serum Concentrations for Selected Parameters

Blood samples were obtained in a fasted state at 8 a.m. and centrifuged immediately. Enzyme immunoassays (ELISA–DRG International, Inc., Springfield, NJ, USA) were used to measure total sRANKL (free and bound RANKL), osteoprotegerin, and a total of 25-OH Vitamin D.

Serum concentrations of parathyroid hormone and calcitonin were determined using the chemiluminescent method (Immulite 1000, Siemens, Tarrytown, NY, USA). Electrochemiluminescence immunoassays (Cobas, Roche Diagnostic, Santa Clara, CA, USA) were used to measure follicle stimulating hormone (FSH), luteinizing hormone (LH), sex hormone-binding globulin (SHBG), testosterone (T), androstenedione, 17-hydroxyprogesterone, estradiol, prolactin (PRL), dehydroepiandrosterone sulfate (DHEA-SO4), glucose, and insulin. The free androgen index (FAI = TT/SHBG × 100%) was used to evaluate free testosterone concentrations.

The analytical sensitivity of the tests was as follows: parathyroid hormone 3.1 pg/mL, calcitonin 2.0 pg/mL, 25-OH vitamin D total 5.6 nmol/L, osteoprotegerin 0.14 pmol/L, leptin 2.0 ng/mL, and sRANKL 0.5 pmol/L. Elisa tests assays were performed as per the manufacturer’s instructions and were quality controlled using the manufacturer’s two-level control set. Samples were run in duplicate. The performance of the microplate reader and microplate washer used for the ELISA determinations and precision was controlled checked with the Pathozyme Elisa Sure kit (Omega Diagnostics, Littleport, UK).

2.3. Bone Mineral Density (BMD) Measurements

Bone mineral density (BMD) measurements were taken at the Endocrinology Clinic at Clinical Hospital No.1, Pomeranian Medical University in Szczecin. BMD was measured in the lumbar spine from the L2 to L4 vertebrae with the use of DEXA (Dual Energy X-ray Absorptiometry), which means the use of double-beam radiation, i.e., simultaneous measurement with a high- and low-energy beam (GE LunarProdigyAdvance, Madison, WI; enCORE software version 8.8). Densitometry was performed using a LUNAR DPX 100 camera (Lunar Corp., Madison, WI, USA).

In all the patients, the quantitative body weight composition (i.e., total body fat (BF), android, and gynoid fat and visceral adipose tissue (VAT), and lean body mass were measured using the DXA method using an automatic whole body scan method. The original manufacturer’s software (Body Composition) was used to determine the individual regions of measurements (female, male, and visceral region).

2.4. Analysis of the CYP19A1 rs700518 Polymorphism

Blood samples were collected at the Department of Endocrinology, Metabolic Diseases, and Internal Diseases, Pomeranian Medical University. CYP19A1 genotyping was performed in the Clinical Laboratory at the Department of Endocrinology, Metabolic Diseases, and Internal Diseases, Pomeranian Medical University. Genomic DNA was extracted from peripheral blood using a QIAamp Blood Mini Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer’s protocol. The CYP19A1 rs700518 polymorphism was selected as per the NCBI SNP database http://www.ncbi.nlm.nih.gov/SNP (accessed on 25 January 2021) and determined by Real-Time PCR using LightCycler 480 and TaqMan®SNP Genotyping Assays (Thermo Fisher Scientific, Waltham, MA, USA). Real-time PCR was performed in a 20 µL reaction mixture according to the manufacturer’s protocol, with initial denaturation at 95 °C for 10 min and 40 cycles as follows: denaturation at 95 °C for 15 s, annealing at 60 °C for 1 min, and cooling at 40 °C for 30 s.

All methods were carried out in accordance with the relevant guidelines and regulations.

2.5. Statistical Analysis

All the statistical analyses for this study were performed using SPSS Statistics 17.0 for Windows. The Chi-square test was used to calculate that the genotype prevalence and allele frequencies were in the Hardy–Weinberg equilibrium. We evaluated the effect of the
CYP19A1 polymorphism on selected biochemical and clinical parameters. Analysis for data distribution was performed using one-way analysis of variance (ANOVA). Values normally distributed were expressed as means ± SEM (standard error of mean).

3. Results

The frequency of genotypes for the CYP19A1 rs700518 polymorphism in women with hyperandrogenism was compared. A higher frequency of the AG genotype (40.0%) was observed compared to the AA (36.2%) and GG (23.8%) genotypes (Table 1). Analysis of the rs700518 polymorphism showed a higher FEI (Free Estradiol Index) value in women with the AG genotype (FEI: GA–8.85 ± 1.18 vs. AA–7.38 ± 1.29, GG–3.30 ± 0.86, p = 0.015) (Table 2).

Table 1. The frequency of alleles and genotypes of the CYP19A1 polymorphism in women with hyperandrogenism.

| CYP19A1 rs700518 | Genotype | Observed Value n (%) | Expected Value (%) |
|------------------|----------|----------------------|--------------------|
| AA               | 29 (36.20) |                      | 31.64              |
| AG               | 32 (40.00) |                      | 49.22              |
| GG               | 19 (23.80) |                      | 19.14              |
| Total            | 80 (100)  |                      | 100                |

The expected value was calculated in accordance with the Hardy–Weinberg equilibrium (HWE).

Table 2. Analysis of female hormonal parameters in relation to CYP19A1 gene polymorphisms in patients with hyperandrogenism.

| Parameter               | CYP19A1 rs700518 | Mean ± SEM | p     |
|-------------------------|------------------|------------|-------|
| Estradiol (pg/mL)       |                  |            |       |
| AA                      | 56.48 ± 8.11     |            | 0.037 |
| AG                      | 60.62 ± 8.12     |            |       |
| GG                      | 34.53 ± 4.12     |            |       |
| FEI (pmol/nmol)         |                  |            |       |
| AA                      | 7.38 ± 1.29      |            | 0.015 |
| AG                      | 8.85 ± 1.18      |            |       |
| GG                      | 3.30 ± 0.86      |            |       |
| Prolactin (ng/mL)       |                  |            |       |
| AA                      | 17.09 ± 1.95     |            | 0.613 |
| AG                      | 16.28 ± 1.34     |            |       |
| GG                      | 20.57 ± 6.35     |            |       |
| 17-OH-Progesterone (ng/mL) |              |            |       |
| AA                      | 1.64 ± 0.37      |            | 0.341 |
| AG                      | 1.31 ± 0.17      |            |       |
| GG                      | 1.04 ± 0.12      |            |       |
| LH (mIU/mL)             |                  |            |       |
| AA                      | 8.99 ± 1.10      |            | 0.474 |
| AG                      | 10.33 ± 1.52     |            |       |
| GG                      | 12.41 ± 3.28     |            |       |
| FSH (mIU/mL)            |                  |            |       |
| AA                      | 7.71 ± 2.08      |            | 0.757 |
| AG                      | 8.14 ± 2.47      |            |       |
| GG                      | 11.00 ± 5.36     |            |       |

FEI—Free Estradiol Index, LH—Luteinizing Hormone, FSH—Follicle Stimulating Hormone. p < 0.05—comparison between genotypes and the parameters analyzed (one-way ANOVA test); values normally distributed are expressed as means ± SEM.
In the participants with the GG genotype, the estradiol concentration was the lowest (Estradiol (pg/mL): GG–34.53 ± 4.12 vs. AA–56.48 ± 8.11, AG–60.62 ± 8.12, p = 0.037). An association with SHGB concentration was also observed, with the highest values found in the GG genotype (SHGB (nmol/L): GG–61.50 ± 10.02 vs. AG–37.43 ± 8.60, AA–34.31 ± 3.73, p = 0.036) (Table 3). BAI (Body Adiposity Index) and androstenedione were lowest in the group with the GG genotype (BAI%: GG–33.77 ± 3.51 vs. AA–45.04 ± 2.63, AG–45.89 ± 2.64, p = 0.011; androstenedione (ng/mL): GG–3.76 ± 0.32 vs. AG–3.89 ± 0.19, AA–4.39 ± 0.51, p = 0.011) (Table 3).

Table 3. Analysis of hormonal parameters in relation to CYP19A1 gene polymorphisms in patients with hyperandrogenism.

| Parameter                   | CYP19A1 rs700518 | Mean ± SEM | p    |
|-----------------------------|------------------|------------|------|
| Testosterone (ng/mL)        |                 |            |      |
| AA                          | 0.51 ± 0.05     | 0.880      |      |
| AG                          | 0.48 ± 0.03     |            |      |
| GG                          | 0.47 ± 0.07     |            |      |
| BAI%                        |                 |            |      |
| AA                          | 45.04 ± 2.63    | 0.011      |      |
| AG                          | 45.89 ± 2.64    |            |      |
| GG                          | 33.77 ± 3.51    |            |      |
| FAI%                        |                 |            |      |
| AA                          | 1.92 ± 0.11     | 0.549      |      |
| AG                          | 1.96 ± 0.11     |            |      |
| GG                          | 1.44 ± 0.15     |            |      |
| Androstendione (ng/mL)      |                 |            |      |
| AA                          | 4.39 ± 0.51     | 0.011      |      |
| AG                          | 3.89 ± 0.19     |            |      |
| GG                          | 3.76 ± 0.32     |            |      |
| DHEA-SO4 (µg/dL)            |                 |            |      |
| AA                          | 248.29 ± 27.60  | 0.700      |      |
| AG                          | 266.44 ± 30.59  |            |      |
| GG                          | 285.60 ± 34.35  |            |      |
| SHBG (nmol/L)               |                 |            |      |
| AA                          | 34.31 ± 3.73    | 0.036      |      |
| AG                          | 37.43 ± 8.60    |            |      |
| GG                          | 61.50 ± 10.02   |            |      |

BAI%—Body Adiposity Index, FAI%—Free Androgen Index, DHEA-SO4—Dehydroepiandrosterone Sulfate, SHGB—Sex Hormone Binding Globulin. p < 0.05—comparison between genotypes and the parameters analyzed (one-way ANOVA test); values normally distributed are expressed as means ± SEM.

However, the most significant of these parameters was the insulin 60'; in this case, the lowest concentration value was also observed for the GG genotype (insulin 60' (µIU/mL): GG–84.67 ± 13.52 vs. AA–145.63 ± 11.01, AG–152.56 ± 18.27, p = 0.007) (Table 4).

Table 4. Analysis of clinical parameters in relation to CYP19A1 gene polymorphisms in patients with hyperandrogenism.

| Parameter                   | CYP19A1 rs700518 | Mean ± SEM | p    |
|-----------------------------|------------------|------------|------|
| Glucose 0' (mg/dL)          |                 |            |      |
| AA                          | 88.88 ± 1.86    | 0.279      |      |
| AG                          | 95.39 ± 4.74    |            |      |
| GG                          | 88.95 ± 1.74    |            |      |
| Glucose 60' (mg/dL)         |                 |            |      |
| AA                          | 137.40 ± 6.23   | 0.353      |      |
| AG                          | 136.86 ± 6.35   |            |      |
| GG                          | 125.29 ± 6.94   |            |      |
Table 4. Cont.

| Parameter          | CYP19A1 rs700518 | Mean ± SEM   | p     |
|--------------------|------------------|--------------|-------|
| Glucose 120' (mg/dL) |                  |              |       |
| AA                 | 107.79 ± 5.06    | 0.995        |       |
| AG                 | 108.54 ± 4.32    |              |       |
| GG                 | 108.43 ± 7.41    |              |       |
| Insulin 0' (µIU/mL) |                  |              | 0.074 |
| AA                 | 20.42 ± 2.85     |              |       |
| AG                 | 35.00 ± 8.50     |              |       |
| GG                 | 16.52 ± 3.43     |              |       |
| Insulin 60' (µIU/mL) |                |              | 0.007 |
| AA                 | 145.63 ± 11.01   |              |       |
| AG                 | 152.56 ± 18.27   |              |       |
| GG                 | 84.67 ± 13.52    |              |       |
| Insulin 120' (µIU/mL) |               |              | 0.158 |
| AA                 | 99.04 ± 17.40    |              |       |
| AG                 | 93.78 ± 10.33    |              |       |
| GG                 | 60.79 ± 15.01    |              |       |
| AG                 | 1.07 ± 0.05      | 0.014        |       |
| AG                 | 1.15 ± 0.05      |              |       |
| GG                 | 0.90 ± 0.07      |              |       |
| VF                 | 719.06 ± 163.57  | 0.043        |       |
| AG                 | 1260.00 ± 197.81 |              |       |
| GG                 | 609.601 ± 206.95 |              |       |

AG—Distribution of android and gynoid fat, VF—Visceral Fat Index. p < 0.05—comparison between genotypes and the parameters analyzed (one-way ANOVA test); values normally distributed are expressed as means ± SEM.

For the indicators of adipose tissue distribution, i.e., AG (distribution of android and gynoid fat) and VF (Visceral Fat Indication), an association was found for the genotypes studied: the GG genotype was associated with lower values of AG and VF (AG: GG–0.90 ± 0.07 vs. AA–1.07 ± 0.05, AG–1.15 ± 0.05, p = 0.014; VF: GG–609.601 ± 206.95 vs. AA–719.06 ± 163.57, AG–1260.00 ± 197.81, p = 0.043) (Table 4). The differences in 25–OH Vitamin D concentration in the individual groups of genotypes were at the border of significance (Vitamin 25 (OH) D (ng/mL): GG–25.33 ± 1.53 vs. AA–21.39 ± 1.60, AG–20.00 ± 1.12, p = 0.05) (Table 5).

Table 5. Analysis of bone metabolism parameters and clinical parameters in relation to CYP19A1 gene polymorphisms in patients with hyperandrogenism.

| Parameter          | CYP19A1 rs700518 | Mean ± SEM | p     |
|--------------------|------------------|------------|-------|
| Vitamin D (ng/mL)  |                  |            | 0.056 |
| AA                 | 15.09 ± 3.16     |            |       |
| AG                 | 11.86 ± 1.44     |            |       |
| GG                 | 21.40 ± 3.27     |            |       |
| 25-OH Vitamin D (ng/mL) |            |            | 0.050 |
| AA                 | 21.39 ± 1.60     |            |       |
| AG                 | 20.00 ± 1.12     |            |       |
| GG                 | 25.33 ± 1.53     |            |       |
| Calcitonin (pg/mL) |                  |            | 0.374 |
| AA                 | 3.52 ± 1.98      |            |       |
| AG                 | 1.27 ± 0.14      |            |       |
| GG                 | 1.86 ± 0.37      |            |       |
| PTH (pg/mL)        |                  |            | 0.275 |
| AA                 | 39.15 ± 4.04     |            |       |
| AG                 | 45.12 ± 4.41     |            |       |
| GG                 | 35.04 ± 4.09     |            |       |
Table 5. Cont.

| Parameter       | CYP19A1 rs700518 | Mean ± SEM   | p     |
|-----------------|------------------|--------------|-------|
| OPG (pmol/L)    | AA               | 3.39 ± 0.21  | 0.471 |
|                 | AG               | 3.78 ± 0.27  |       |
|                 | GG               | 3.73 ± 0.27  |       |
| sRANKL (pmol/L) | AA               | 262.56 ± 52.38 |    |
|                 | AG               | 188.85 ± 18.19 |   |
|                 | GG               | 190.51 ± 18.91 |   |

PTH—Parathyroid hormone, OPG—Osteoprotegerin, BMI—Body Mass Index. p < 0.05—comparison between genotypes and the parameters analyzed (one-way ANOVA test); values normally distributed are expressed as means ± SEM.

Concentrations of the remaining parameters of the CYP19A1 rs700518 polymorphism: 17-OH-progesterone, LH, FSH, testosterone, FAI%, DHEA-SO4, glucose 0’, glucose 60’, glucose 120’, insulin 0’, insulin 120’, vitamin D levels, calcitonin, PTH, OPG, sRANKL, BMD total, BMD L1–L4, T-score, Z-score, BMI, BMC, and TBS in relation to the distribution of individual genotypes (AA, AG, GG) showed no statistically significant differences (Table 6).

Table 6. Analysis of bone metabolism parameters in relation to CYP19A1 gene polymorphisms in patients with hyperandrogenism.

| Parameter       | CYP19A1 rs700518 | Mean ± SEM   | p     |
|-----------------|------------------|--------------|-------|
| BMD total       | AA               | 1.18 ± 0.03  | 0.169 |
|                 | AG               | 1.22 ± 0.02  |       |
|                 | GG               | 1.16 ± 0.02  |       |
| BMD L1–L4       | AA               | 1.22 ± 0.03  | 0.366 |
|                 | AG               | 1.25 ± 0.03  |       |
|                 | GG               | 1.19 ± 0.03  |       |
| T-score         | AA               | 0.34 ± 0.32  | 0.267 |
|                 | AG               | 0.24 ± 0.24  |       |
|                 | GG               | 0.27 ± 0.27  |       |
| Z-score         | AA               | 0.32 ± 0.29  | 0.861 |
|                 | AG               | 0.21 ± 0.28  |       |
|                 | GG               | 0.10 ± 0.18  |       |
| BMI             | AA               | 27.85 ± 1.45 | 0.055 |
|                 | AG               | 32.63 ± 2.03 |       |
|                 | GG               | 26.27 ± 2.19 |       |
| BMC (g)         | AA               | 2403.84 ± 62.69 |    |
|                 | AG               | 2452.41 ± 41.97 |   |
|                 | GG               | 2328.36 ± 57.87 |   |
| TBS             | AA               | 1.34 ± 0.04  | 0.361 |
|                 | AG               | 1.40 ± 0.03  |       |
|                 | GG               | 1.34 ± 0.03  |       |

BMC—Bone Mineral Content, BMD L1–L4—Bone Mineral Density L1–L4, T-score—the ratio of the bone mineral density (BMD) of the participant to the average bone density of a young person, Z-score—bone mineral density index, BMD total—Bone Mineral Density total, TBS—Trabecular Bone Score. p < 0.05—comparison between genotypes and the parameters analyzed (one-way ANOVA test); values normally distributed are expressed as means ± SEM.

4. Discussion

The CYP19 gene codes for the aromatase enzyme that converts androgens into estrogens. Any change in the expression of the CYP19A1 gene may alter the levels of androgens and estrogens in the female body. It was found that normal aromatase activity is essential for the proper development of ovarian follicles during fetal development, their maturation, and during ovulation in the reproductive period. A deficiency of aromatase in most cases leads to the development of a polycystic ovary phenotype [12]. The CYP19A1 rs700518
polymorphism is based on the conversion of adenine (A) to guanine (G) and is one of the most widely studied polymorphisms in relation to bone mineral density (BMD) and osteoporosis. Such a change may affect the post-transcriptional regulation of the gene, leading to a change in its expression and, consequently, changes in the concentration of aromatase and androgens [13,14].

Many authors have observed that CYP19A1 gene mutations are associated with BMD and their presence may contribute to the development of osteoporosis [10,15]. Riancho et al. and Kaminski et al. showed that total hip BMD is higher in patients with the GG genotype compared to the GA and AA genotypes [15,16].

In a meta-analysis by Hua-Jing Ma, it was demonstrated that the AG genotype of the rs700518 polymorphism is associated with low BMD and plays a role in the development of osteoporosis. These studies are in line with our results, which indicate that the AG genotype is most associated with the risk of osteoporosis [17]. In addition, Kaminski et al. demonstrated a higher frequency of the AG genotype compared to GG and AA in women with postmenopausal osteoporosis [15]. However, the results of the studies are often ambiguous, and few have demonstrated a significant effect of the rs700518 polymorphism on BMD [18,19].

Aguirre et al. observed that the expression of the CYP19A1 gene was highest in the group with the rs700518 SNP polymorphism in the GG genotype [20]. In our study, the analysis of the rs700518 polymorphism of the CYP19A1 gene showed an association of FEI on the GG genotype vs. AG and AA. The FEI value is the ratio of the estradiol concentration to the SHGB concentration. In our study, we also found a relationship between the concentration of SHGB and estradiol (components of the FEI formula) on the genotype of GG vs. AG and AA. With the GG genotype, the concentrations of SHGB were higher and the concentration of estradiol was lower. Ebrahimi et al. observed a strong correlation between the GG genotype of the rs700518 polymorphism and a lower estradiol concentration compared to the AA genotype in all the women studied. The authors showed a relationship between the severity of acne vulgaris and the frequency of the GG genotype of the polymorphism studied [21].

The level of sex hormones influences the distribution of adipose tissue. Estrogens are responsible for the fat distribution typical of women, which accumulates mainly in the subcutaneous tissue around the thighs and buttocks [22,23]. In our group of women with hyperandrogenism, we observed an association of the adipose tissue distribution indices (BAI, AG, and VF) with the GG, AA, and AG genotypes of the CYP19A1 rs700518 polymorphism. In women receiving aromatase inhibitors, Napoli et al. found a relationship between the increase in body fat on the GG genome for the rs700518 SNP in the CYP19A1 gene, but did not observe a similar phenomenon for the AG and AA genomes [24]. In our study, the GG genotype was associated with the lowest VF value (Visceral Fat Index), which is a measure of the amount of visceral fat. Visceral adipose tissue (VAT) is considered to be the main risk factor for the development of certain cardiovascular, metabolic, oncological, and autoimmune diseases. VAT is also a risk factor for early death [25,26]. An increased volume of visceral fat leads to a reduction in bone mineral density (BMD). In turn, a reduction in BMD represents an increased risk of developing osteoporosis [17]. Additionally, the Body Adiposity Index (BAI%) in the women we studied showed an association with individual genotypes: the lowest value was observed for the GG genotype, and the highest for AG. The distribution of the android and genoid fat (AG) index indicates the male (abdominal) or female type of fat distribution in the body. In our study of the rs700518 polymorphism, among women with hyperandrogenism, the AG index value was lowest in the GG genotype group and highest in the AG genotype group. Summarizing the influence of the CYP19A1 rs700518 polymorphism in our group of hyperandrogenic women, we observed an association between the homozygous GG genotype and the amount and distribution of adipose tissue. Women with the GG genome had the lowest BAI% and the lowest percentage of adipose tissue in total body weight; moreover, its distribution was the most consistent with the female pattern adipose tissue distribution, and AG.
and VF rates were the lowest. The group of women with the GG genotype also had the lowest average body weight. Another interesting observation was the finding of a strong relationship between the GG genotype and the lowest insulin level 1 h after the 75 g oral glucose tolerance test (OGTT). The relationship between aromatase activity, glucose metabolism, and insulin sensitivity has been noted by many researchers. Chen et al. noticed a decrease in glucose concentration in OGTT in a patient with aromatase deficiency after the administration of estrogens. This confirms that aromatase activity lowers the level of glycemia by influencing the level of estrogens. These researchers, however, did not find that estradiol improved insulin resistance; after 6 months administering 25 µg of transdermal estradiol (Estraderm TTS, Novartis) twice a week, the fasting insulin level was 2.66 times higher than at the beginning of the study [27,28]. In our study, we observed an association between the GG genotype and lower insulin 60' levels, but we did not observe significant differences in glucose levels in OGTT for individual genotypes.

In our study, the GG genotype was associated with the lowest content of visceral adipose tissue and the lowest ratio of android to gynoid adipose tissue. It has been proven that adipose tissue as an additional endocrine organ is a source of adipokines, hormones, cytokines, and other substances that adversely affect carbohydrate metabolism, including those increasing the risk of insulin resistance [29].

The influence of the CYP19A1 rs700518 polymorphism on the bone metabolism of hyperandrogenic women was assessed by examining the following parameters: BMC—Bone Mineral Content, TBS—Trabecular Bone Score, BMD L1–L4—Bone Mineral Density L1–L4, T-score—the ratio of the bone mineral density (BMD) of the participant to the average bone density of a young person, Z-score—bone mineral density index, and BMD total—Bone Mineral Density total. Oz et al. confirmed the numerous occurrences of aromatase in bone tissue, chondrocytes, and osteoblasts [30]. On the other hand, Liu et al. demonstrated that the activity of aromatase encoded by the CYP19A1 gene may have a significant impact on bone health, and women with lower activity of this enzyme may be more likely to have osteoporosis [31]. We did not observe statistically significant differences between the above parameters of bone metabolism between individual genotypes. Only a clear difference was observed for the Z-score, but it was not statistically significant. These Z-scores mean that the bone density in the GG group was closer to the average for a given age, and the women from the AA group had higher bone density than the average for a given age; an approximate Z-score = 0.1 corresponds to the 50th percentile and Z-score = 0.3 corresponds to the 60th percentile.

5. Conclusions

The study showed that the CYP19A1 gene rs700518 polymorphism may be associated with the distribution of adipose tissue in young women with hyperandrogenism. The data showed that the GG genotype of the CYP19A1 rs700518 polymorphism is associated with the lowest FEI, the highest SHGB, and the highest estradiol concentration and insulin concentration determined in the glucose tolerance test 60' compared to the AG and AA genotypes.

On the other hand, the distribution of adipose tissue in women is an important factor affecting BMD, which may be associated with the risk of osteoporosis. Patients with the AG genotype had a significantly higher ratio of android to gynoid fat and a greater content of visceral adipose tissue. Higher visceral tissue content may reduce BMD. Patients with the AG genotype may develop osteoporosis. It seems that the CYP19A1 rs700518 polymorphism may be a potential marker used in the early prevention, diagnosis, and therapy of osteoporosis. However, more research is needed, involving more patients.

Author Contributions: I.U.—conceptualization, methodology, and original draft preparation. A.B.—validation and formal analysis and original draft preparation. E.S.—P.—analysis of data and writing—review and editing. K.P.—original draft preparation. F.P.—collecting literature, methodology, and software. M.W.—writing—review and editing. B.C.—project administration, leadership, and supervision. All authors have read and agreed to the published version of the manuscript.
Funding: The study was supported by statutory projects from the Institute of Natural Fibers and Medicinal Plants and the Pomeranian Medical University in Szczecin (Poland).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sowinska-Przepiera, E.; Chelstowski, K.; Friebie, Z.; Syrenicz, A. Bone mineral density in girls with functional hypothalamic amenorrhea subjected to estroprogestagen treatment—a 4-year prospective study. *Gynecol. Endocrinol.* 2011, 27, 966–970. [CrossRef] [PubMed]

2. Liu, J.H.; Bill, A.H. Stress-associated or functional hypothalamic amenorrhea in the adolescent. *Ann. N. Y. Acad. Sci.* 2008, 1135, 179–184. [CrossRef] [PubMed]

3. Bomba, M.; Gambera, A.; Bonini, L.; Peroni, M.; Neri, F.; Scagliola, P.; Nacinovich, R. Endocrine profiles and neuropsychologic correlates of functional hypothalamic amenorrhea in adolescents. *Fertil. Steril.* 2007, 87, 876–885. [CrossRef] [PubMed]

4. Sowinska-Przepiera, E.; Niedzielska, M. Hiperandrogenizm u kobiet jako problem kliniczny, diagnostyczny i terapeutyczny. Prz. Lek. 2018, 75, 405–410.

5. Unluhizari, K.; Kaltas, G.; Kelestimer, F. Non polycystic ovary syndrome-related endocrine disorders associated with hirsutism. *Eur. J. Clin. Investig.* 2012, 42, 86–94. [CrossRef]

6. Longcope, C. Adrenal and gonadal androgen secretion in normal females. *Clin. Endocrinol. Metab.* 1986, 15, 213–228. [CrossRef]

7. Simpson, E.R.; Mahendroo, M.S.; Means, G.D.; Kilgore, M.W.; Hinshelwood, M.M.; Graham-Lorence, S.; Amarneh, B.; Ito, Y.; Fisher, C.R.; Dodson Michael, M.; et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. *Endocr. Rev.* 1994, 15, 342–355.

8. Chen, S.; Besman, M.J.; Sparkes, R.S.; Zollman, S.; Klisak, I.; Mohandas, T.; Hall, P.F.; Shively, J.E. Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome. *DNA 1988*, 7, 27–38. [CrossRef]

9. Bulun, S.E. Aromatase deficiency. *Fertil. Steril.* 2014, 101, 323–329. [CrossRef]

10. Kastelan, D.; Grubic, Z.; Kraljevic, I.; Duric, K.; Kardum, I.; Dusek, T.; Stingl, K.; Giljevic, Z.; Kerhin-Brkljacic, V.; Suchanek, E.; et al. Decreased peak bone mass is associated with a 3-bp deletion/insertion of the CYP19 intron 4 polymorphism: Preliminary data from the GOOS study. *J. Endocrinol. Investig.* 2007, 30, 465–469. [CrossRef]

11. Masi, L.; Becherini, L.; Gennari, L.; Amedei, A.; Colli, E.; Falchetti, A.; Farci, M.; Silvestri, S.; Connelli, S.; Brandi, M.L. Polymorphism of the aromatase gene in postmenopausal Italian women: Distribution and correlation with bone mass and fracture risk. *J. Clin. Endocrinol. Metab.* 2001, 86, 2263–2269. [CrossRef] [PubMed]

12. Preaveen, V.P.; Ladjuze, A.; Sauter, K.S.; Pulickal, A.; Katharopoulos, E.; Trippel, M.; Perren, A.; Pandey, A.V.; Flück, C.E. Novel CYP19A1 Mutations Extend the Genotype-Phenotype Correlation and Reveal the Impact on Ovarian Function. *CYP19A1* 2020, 4, bvaa030. [CrossRef] [PubMed]

13. Sowers, M.R.; Wilson, A.L.; Kardia, S.R.; Chu, J.; Ferrell, R. Aromatase Gene (CYP 19) Polymorphisms and Endogenous Androgen Concentrations in a Multiracial/Multiethnic, Multisite Study of Women at Midlife. *Am. J. Med.* 2006, 119, 23–30. [CrossRef] [PubMed]

14. Napoli, N.; Rastelli, A.; Ma, C.; Yarramaneni, J.; Vattikutti, S.; Moskowitz, G.; Girì, T.; Mueller, C.; Cullkarny, V.; Qualls, C.; et al. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer. *Bone 2013*, 55, 309–314. [CrossRef]

15. Kamiński, A.; Bogacz, A.; Górska-Paukszta, M.; Seremak-Mrozikiewicz, A.; Czerny, B. Correlation of rs749292 and rs700518 Concentrations in a Multiracial/Multiethnic, Multisite Study of Women at Midlife. *Bone 2013*, 55, 309–314. [CrossRef]

16. Praveen, V.P.; Ladjouze, A.; Sauter, K.S.; Pulickal, A.; Katharopoulos, E.; Trippel, M.; Perren, A.; Pandey, A.V.; Flück, C.E. Novel CYP19A1 Mutations Extend the Genotype-Phenotype Correlation and Reveal the Impact on Ovarian Function. *J. Endocr. Soc.* 2020, 4, bvaa030. [CrossRef] [PubMed]

17. Somner, J.; McLellan, S.; Cheung, J.; Mak, Y.T.; Frost, M.L.; Knapp, K.M.; Wierzbiicki, A.S.; Wheeler, M.; Fogelman, I.; Ralston, S.H.; et al. Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: Association with serum sex steroid concentrations and bone mineral density in postmenopausal women. *J. Clin. Endocrinol. Metab.* 2004, 89, 344–351. [CrossRef]

18. Junying, S.; Zhang, Q. Association of cytochrome p450 gene CYP19 polymorphism with bone mineral density in postmenopausal Anhui Province women. *Anhui. Med. Pharm. J.* 2010, 14, 548–550.
20. Aguirre, L.E.; Colleluori, G.; Robbins, D.; Dorin, R.; Shah, V.O.; Chen, R.; Jan, I.Z.; Qualls, C.; Villareal, D.T. Armamento-Villareal, R. Bone and body composition response to testosterone therapy vary according to polymorphisms in the CYP19A1 gene. *Endocrine* 2019, 65, 692–706. [CrossRef]

21. Ebrahimi, A.; Rahimi, Z.; Ghadami, Z.; Shakiba, E.; Rahimi, Z.; Akbari, M.; Shafiei, M.; Bahrehmand, F.; Vaisi-Raygani, A.; Naseri, R. Association between CYP19A>G rs700518 Polymorphism with Acne Vulgaris and its Severity: Influence on Sex Hormones Level. *Int. J. Mol. Cell. Med.* 2019, 8, 162–168. [PubMed]

22. Giorgino, F.; Laviola, L.; Eriksson, J.W. Regional differences of insulin action in adipose tissue: Insights from in vivo and in vitro studies. *Acta. Physiol. Scand.* 2005, 183, 13–30. [CrossRef] [PubMed]

23. Tchernof, A.; Belanger, C.; Morisset, A.S.; Richard, C.; Mailloux, J.; Laberge, P.; Dupont, P. Regional differences in adipose tissue metabolism in women: Minor effect of obesity and body fat distribution. *Diabetes* 2006, 55, 1353–1360. [CrossRef] [PubMed]

24. Napoli, N.; Rastelli, A.; Ma, C.; Yarramaneni, J.; Vattikutti, S.; Moskowitz, G.; Giri, T.; Mueller, C.; Kulkarny, V.; Qualls, C.; et al. Genetic Polymorphism at Val⁸⁰ (rs700518) of the CYP19A1 Gene is Associated with Body Composition Changes in Women on Aromatase Inhibitors for ER (+) Breast Cancer. *Pharmacogenet. Genom.* 2015, 25, 377–381. [CrossRef] [PubMed]

25. Samouda, H. Commentary: Anthropometric Indicators as a Tool for Diagnosis of Obesity and Other Health Risk Factors: A Literature Review. *Front. Psychol.* 2021, 12, 750613. [CrossRef] [PubMed]

26. Brown, J.C.; Harhay, M.O.; Harhay, M.N. Anthropometrically-predicted visceral adipose tissue and mortality among men and women in the third national health and nutrition examination survey (NHANES III). *J. Clin. Med.* 2017, 29, e22898. [CrossRef] [PubMed]

27. Chen, Z.; Wang, O.; Nie, M.; Elison, K.; Zhou, D.; Li, M.; Jiang, Y.; Xia, W.; Meng, X.; Chen, S.; et al. Aromatase deficiency in a Chinese adult man caused by novel compound heterozygous CYP19A1 mutations: Effects of estrogen replacement therapy on the bone, lipid, liver and glucose metabolism. *Mol. Cell. Endocrinol.* 2015, 399, 32–42. [CrossRef]

28. Santen, R.J.; Brodie, H.; Simpson, E.R.; Sitteri, P.K.; Brodie, A. History of aromatase: Saga of an important biological mediator and therapeutic target. *Endocr. Rev.* 2009, 30, 343–375. [CrossRef]

29. Maffei, L.; Murata, Y.; Rochira, V.; Tubert, G.; Aranda, C.; Vazquez, M.; Clyne, C.D.; Davis, S.; Simpson, E.R.; Carani, C. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: Effects of testosterone, alendronate, and estradiol treatment. *J. Clin. Endocrinol. Metab.* 2004, 89, 61–70. [CrossRef]

30. Oz, O.K.; Millsaps, R.; Welch, R. Expression of aromatase in the human growth plate. *J. Mol. Endocrinol.* 2001, 27, 249–253. [CrossRef]

31. Liu, H.J.; Yan, J.; Li, Y.; Zhou, F.Y.; Su, X.D.; Fan, H.J.; Bai, J.; Zhang, G.Z. Low Aromatase Activity and Estradiol/Sex Hormone Binding Globulin Ratio are Associated with Total Hip Bone Mineral Density and the Presence of Osteoporosis: A Study in Chinese Postmenopausal Women. *Horm. Metab. Res.* 2018, 50, 65–72. [CrossRef] [PubMed]